NICE Recommends Enhertu for Earlier-Stage Advanced Breast Cancer

The UK’s National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) for advanced breast cancer that is at an earlier-stage.

The recommendation is based on clinical trial evidence showing that Enhertu increases the time patients have before the disease progresses compared to the standard-of-care treatment with trastuzumab emtansine.

However, NICE is not recommending Enhertu for routine National Health Service use because a clinical trial evaluating the drug is ongoing, making the cost-effectiveness estimates very uncertain.